Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
ExportLink to record
Permanent link

Direct link
BETA

Project

Project type/Form of grant
Project grant
Title [sv]
Blodkärlen som mål för cancerterapi i hjärntumörer
Title [en]
The vasculature as a target for therapy in brain tumors
Abstract [en]
Glioblastomas are aggressive gliomas with a grim prognosis, characterized extreme invasiveness and abnormal vessels. The abnormal vessels can promote tumor progession by providing a route of invasion for glioma cells and by limiting T cell recruitment.  We have found that the C-type lectin CD93 is highly expressed in glioblastoma vessels and is important for organizing fibronectin in extracellular matrix. Our current data suggest that CD93 is necessary for migration of glioma cells along blood vessels. The first aim of this proposal is to explore the mechanisms through which CD93 promotes perivascular migration, to find  therapeutic targets to block invasion. Here, we combine analysis of human glioblastomas with high quality in vitro and in vivo models of glioma invasion. The efficacy of cancer immunotherapy is hampered by an immunosuppressive microenvironment in glioblastoma. Tumor vessels respond poorly to pro-inflammatory signals and express low levels of adhesion molecules and chemokines needed for T cell recruitment.  In the second aim of this proposal, we take a new approach to enhancing T cell recruitment, by transforming tumor vessels to a phenotype that resembles high endothelial venules (HEV) of lymphoid organs. Therapeutic induction of HEV will be performed using an AAV-vector that target brain endothelal cells, and the effects will be investigated in experimental models of glioma. Our goal is to find new vascular targeting strategies to improve patient prognosis.
Publications (2 of 2) Show all publications
Barbera, S., Schuiling, M. J. A., Sanjaya, N. A., Pietilä, I., Sarén, T., Essand, M. & Dimberg, A. (2025). Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains. Science immunology, 10(103), Article ID eado2054.
Open this publication in new window or tab >>Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains
Show others...
2025 (English)In: Science immunology, E-ISSN 2470-9468, Vol. 10, no 103, article id eado2054Article in journal (Refereed) Published
Abstract [en]

Trogocytosis is an exchange of membrane-associated molecules between cells that can either halt or boost immune responses. However, the mechanism that regulates trogocytosis in T cells and its consequences are not yet clear. Here, we demonstrate that T cells can exchange chimeric antigen receptors (CARs) by trogocytosis, thereby arming recipient T cells with the capacity to respond to tumor antigens by up-regulating proteins associated with a cytotoxic response and killing of target cells. We demonstrate that although trogocytosis is dependent on cell-cell contact, the exchange of a specific cell membrane protein does not require a cognate binding partner on the surface of recipient cells. Instead, the probability that a protein is exchanged by trogocytosis is determined by its transmembrane domain. This finding opens new avenues for modulating this process in CAR-T cells.

Place, publisher, year, edition, pages
American Association for the Advancement of Science (AAAS), 2025
National Category
Immunology in the medical area Cancer and Oncology Cell and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-550398 (URN)10.1126/sciimmunol.ado2054 (DOI)001410064400001 ()39888980 (PubMedID)2-s2.0-85217623953 (Scopus ID)
Funder
Swedish Cancer Society, 20 1008 PjSwedish Cancer Society, 20 1010 UsSwedish Cancer Society, 22 2241 PjSwedish Cancer Society, 230722PTSwedish Cancer Society, PR2020-0167Swedish Cancer Society, PR2021-0122Sjöberg Foundation, 2020-01-07:06Sjöberg Foundation, 2023-01-01:6Swedish Research Council, 2019-01326Swedish Research Council, 2020-02563Knut and Alice Wallenberg Foundation, 2019.0088
Note

De två sista författarna delar sistaförfattarskapet

Available from: 2025-02-19 Created: 2025-02-19 Last updated: 2025-02-19Bibliographically approved
Vemuri, K., de Alves Pereira, B., Fuenzalida, P., Subashi, Y., Barbera, S., van Hooren, L., . . . Dimberg, A. (2024). CD93 maintains endothelial barrier function and limits metastatic dissemination. JCI Insight, 9(7), Article ID e169830.
Open this publication in new window or tab >>CD93 maintains endothelial barrier function and limits metastatic dissemination
Show others...
2024 (English)In: JCI Insight, ISSN 2379-3708, Vol. 9, no 7, article id e169830Article in journal (Refereed) Published
Abstract [en]

Compromised vascular integrity facilitates extravasation of cancer cells and promotes metastatic dissemination. CD93 has emerged as a target for antiangiogenic therapy, but its importance for vascular integrity in metastatic cancers has not been evaluated. Here, we demonstrate that CD93 participates in maintaining the endothelial barrier and reducing metastatic dissemination. Primary melanoma growth was hampered in CD93–/– mice, but metastatic dissemination was increased and associated with disruption of adherens and tight junctions in tumor endothelial cells and elevated expression of matrix metalloprotease 9 at the metastatic site. CD93 directly interacted with vascular endothelial growth factor receptor 2 (VEGFR2) and its absence led to VEGF-induced hyperphosphorylation of VEGFR2 in endothelial cells. Antagonistic anti-VEGFR2 antibody therapy rescued endothelial barrier function and reduced the metastatic burden in CD93–/– mice to wild-type levels. These findings reveal a key role of CD93 in maintaining vascular integrity, which has implications for pathological angiogenesis and endothelial barrier function in metastatic cancer.

Place, publisher, year, edition, pages
American Society For Clinical Investigation, 2024
National Category
Cancer and Oncology Cell and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-527236 (URN)10.1172/jci.insight.169830 (DOI)001201729000001 ()38441970 (PubMedID)
Funder
Swedish Cancer Society, CAN 2017/502Swedish Cancer Society, 20 1008 PjFSwedish Cancer Society, 20 1010 UsFSwedish Cancer Society, CAN 2015/1216Swedish Cancer Society, 23 3098 PjSwedish Childhood Cancer Foundation, PR2018-0148Swedish Childhood Cancer Foundation, PR2021-0122Swedish Research Council, 2020-02563Knut and Alice Wallenberg Foundation, KAW 2019.0088
Note

De två sista författarna delar sistaförfattarskapet

Available from: 2024-04-29 Created: 2024-04-29 Last updated: 2024-04-29Bibliographically approved
Principal InvestigatorDimberg, Anna
Coordinating organisation
Uppsala University
Funder
Period
2021-01-01 - 2024-12-31
National Category
Cell and Molecular BiologyImmunology in the medical area
Identifiers
DiVA, id: project:6496Project, id: 2020-02563_VR

Search in DiVA

Cell and Molecular BiologyImmunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar